Introduction: Since the onset of the SARS-CoV-2 pandemic in March 2019, scientists have been trying first to define the virus, the disease and even the factors that exacerbate the situation. Questions have arisen about the relationship between the patient's blood type, rhesus and the development of a COVID-19 infection. The purpose of this study is to determine whether or not there is a correlation between blood types, rhesus and COVID-19 disease, as well as its severity. Material and methods: We conducted a retrospective study of 7 months from August 2021 to February 2022, involving 59 patients with 33 male and 26 female subjects suspected of being infected with COVID-19, between the ages of 14 and 90. These patients were recruited from the Pasteur Institute "Oran Annex" and the Local Public Health Facility (EPSP BENI SAF). RT-qPCR techniques and blood grouping were used to determine the blood type of patients and whether or not they were infected with the SARS-CoV-2 virus. Patient information was retrieved from both facilities from medical records. Results: According to our results, 83% of patients tested positive for SARS-CoV-2 and 17% tested negative. The proportion of the O-group among those infected with SARS-CoV-2 (66%) was lower than in healthy patients (70%), while the proportion of the A-group (20%) was higher in negative patients than in positive patients (17%). The percentage of blood type B was identical in the affected and healthy groups (10%), while the AB group was present in affected patients (7%) and was completely absent in healthy patients. The p-value was 1 and this indicates that the link between blood type and COVID-19 infection is not significant. Conclusions: In light of our findings, there is a correlation between rhesus and the age of patients during the development of COVID-19 infection.

Introduction: Breast carcinoma is a heterogeneous pathology. These subtypes are known to vary in terms of risk factors, natural histories and responses to therapies. The prognostic classification based on gene expression and genomic profiling was implemented to refine therapeutic indications and improve patient survival. Our goal is to classify infiltrating channel carcinomas according to their molecular profiles and analyze the different clinicopathological variables of these molecular groups. Material and methods: We conducted a 24-month retrospective study involving 50 patients recruited from the Oran University Hospital and the Oran Regional Military Hospital. Tumors were analyzed histologically and classified after an immunohistochemical study in groups: luminal A, luminal B, Her2+ and basal-like. Results: Our study showed the predominance of molecular subtype luminal B (36%) of which 55.56% of these tumors were of Scarff-Bloom-Richardson (SBR) grade II and 44% were of grade III. 55.56% were T2 size followed by T1 size with a percentage of about 33.33%. Axillary ganglionic metastases were found in 88.89% of cases, followed by luminal A (32%) with 62.5% grade III, and 37.5% grade SBR II. Thus 37.5% of these tumors were of stage T2 and T4. Axillary ganglionic metastases were present in 87.5%. The HER2 type (20%) with 60% SBR II grade and 40% grade III. All basal-like tumors represented the highest SBR grade III with a percentage of 100%. Conclusions: Molecular classification is crucial in the direction of treatment.